NDLI: Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Please wait, while we are loading the content...

Year: 2017 Volume: 40

Year: 2016 Volume: 39

Year: 2015 Volume: 38

Year: 2014 Volume: 37

Year: 2013 Volume: 36

Year: 2012 Volume: 35

Year: 2011 Volume: 34

Year: 2010 Volume: 33

Year: 2010 Volume: 33 Issue: 12

Year: 2010 Volume: 33 Issue: 11

Year: 2010 Volume: 33 Issue: 10

Year: 2010 Volume: 33 Issue: 9

Year: 2010 Volume: 33 Issue: 8

Year: 2010 Volume: 33 Issue: 7

Year: 2010 Volume: 33 Issue: 6

Year: 2010 Volume: 33 Issue: 5

Year: 2010 Volume: 33 Issue: 4

Year: 2010 Volume: 33 Issue: 3

Year: 2010 Volume: 33 Issue: 2

Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.

Antipsychotic-induced hyponatraemia: a systematic review of the published evidence.

Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study.

Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Wonder vigilance.

Year: 2010 Volume: 33 Issue: 1

Year: 2009 Volume: 32

Year: 2008 Volume: 31

Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Wierzbicki, Anthony S. Viljoen, Adie
Description	Country affiliation: United kingdom Author Affiliation: Wierzbicki AS ( Guy's and St Thomas' Hospitals, London SE1 7EH, UK. Anthony.Wierzbicki@kcl.ac.uk)
Abstract	Atherosclerosis begins in childhood with the formation of fatty streaks. Early plaques can be found in adolescence and early coronary disease can be found in young adults. It has been suggested that early treatment may lead to great benefits in later life. This article is a narrative review of the role of lipid-lowering drug therapy in paediatric practice. Increased rates of atherosclerosis are known to occur in children with familial hypercholesterolaemia (FH), especially in homozygotes. There is evidence for the efficacy and safety of lipid-lowering therapies in children, particularly with respect to the effects of HMG-CoA reductase inhibitors (statins) on lipids and, to a limited extent, on other surrogate measures of atherosclerosis in patients with FH. Diagnosis of FH and its early treatment are recommended in all guidelines. Lipid-lowering drug therapy is recommended for the treatment of homozygous FH at all ages and from as young as 10 years of age for the treatment of heterozygous FH when there is a family history of very premature coronary heart disease (occurring at age <40 years). Controversy exists about other possible indications. Increased rates of atherosclerosis are seen in autoimmune disorders, including type 1 diabetes mellitus, systemic lupus erythematosus and Kawasaki's disease, and in transplant recipients. All evidence in these areas is derived by extrapolation from studies in adults. These disorders can be divided into those for which percutaneous coronary intervention is performed early and/or for which drugs used to treat the primary disorder increase the rate of atherosclerosis, and those for which this is not the case. In both cardiac transplantation and Kawasaki's disease, increased atherosclerosis can occur as a result of (i) disease-related vasculopathy; or (ii) increased restenosis secondary to interventions. Statins have a good evidence base for reducing rates of re-occlusion following coronary artery procedures, and this justifies their use in these settings. In renal transplantation, statins may have a role to play in patients with persistent dyslipidaemia and additional cardiovascular risk factors. In other disorders, such as type 1 diabetes, the disease process is atherogenic and thus statins may be justified in patients with a long history of disease (>10 years), poor control, and evidence of vascular or endothelial damage or additional cardiovascular risk factors. There is a role for lipid-lowering therapies in children at high risk of atherosclerosis, but the evidence base outside of FH is weak. Lipid-lowering therapy should be prescribed to all children with homozygous or severe heterozygous FH. Based on adult evidence, statin therapy should be considered in patients who have undergone coronary artery procedures or received cardiac transplants, in whom their primary role is to prevent vascular re-occlusion. In diseases associated with a chronic increased atherogenic risk, such as type 1 diabetes, statins should be considered in high-risk cases where additional cardiovascular risk factors are present. At present, the most important need is for trials to be performed in children using accepted surrogate endpoints to define whether lipid-lowering drug therapy is beneficial in this group.
File Format	HTM / HTML
ISSN	01145916
Issue Number	2
Volume Number	33
e-ISSN	11791942
Journal	Drug Safety
Language	English
Publisher	Springer
Publisher Date	2010-02-01
Publisher Place	New Zealand (Aotearoa)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Toxicology Hydroxymethylglutaryl-coa Reductase Inhibitors Therapeutic Use Hyperlipidemias Drug Therapy Adolescent Child Humans Pediatrics Risk Factors Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Toxicology Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in